Article
Multi-omics joint analysis to explore new therapeutic targets for Crohn's disease
2023-08-17
Abstract excerpt
<h4>Background: </h4> Infliximab (IFX), the mainstay of current treatment for moderate-to-severe Crohn's disease (CD), markedly improved clinical symptoms and quality of life for patients. However, not all patients can benefit from IFX. This study aims to identify new therapeutic targets for primary nonresponders through combination of transcriptomic and proteomic analyses. Methods The plasma and peripheral leuko...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f4d022c7-b959-5966-979c-e8601c1b1b8b
- DOI
- 10.21203/rs.3.rs-3241938/v1
